Takeda Pharmaceutical Company Limited / Keyword(s): Forecast
Takeda Pharmaceutical Company Limited: Notice of Revision of Fiscal Year 2021 Consolidated Financial Statement Guidance (IFRS)

03-Feb-2022 / 07:00 CET/CEST
Disclosure of privileged information according to. in Article 17 MAR of Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notice of revised forecasts of the consolidated financial statements for the financial year 2021 (IFRS)

Osaka, Japan, February 3, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced revised guidance to the consolidated financial statements for the fiscal year ended March 31, 2022, as below.

1. Revised guidance for the full year consolidated financial statements for the year ending March 31, 2022

(million yen)

^* Announced October 28, 2021.

2. Reasons for the revision

In light of Takeda’s financial results for the nine-month period ended December 31, 2021, the full-year financial guidance for revenue and profit has been revised from the previous guidance announced on October 28, 2021, reflecting favorable exchange rates, strong business momentum across Takeda’s 14 global brands and discipline in operating expenses. The upward revision to forecasts is also attributable to other assumptions, including discounted tax rate assumptions.

3. Management tips

Management guidelines have not changed from previous guidelines.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader, headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided through our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare genetics and hematology, neurosciences and gastroenterology (GI). We also make targeted R&D investments in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by pushing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline and diversified in terms of modalities. Our employees are committed to improving the quality of life for patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

contacts:

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) relating to this release. This press release (including any oral presentation and any Q&As relating thereto) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer for purchase, otherwise acquire, subscribe, exchange, sell or otherwise dispose of securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are offered to the public by means of this press release. No offer of securities will be made in the United States except pursuant to registration under the US Securities Act of 1933, as amended, or an exemption therefrom. This press release is given (together with any other information which may be provided to the recipient) on the condition that it is to be used by the recipient for informational purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly hold investments are separate entities. In this press release, “Takeda” is sometimes used for convenience when referring to Takeda and its affiliates generally. Similarly, the words “we”, “us” and “our” are also used to refer to affiliates in general or the people who work for them. These expressions are also used when it is not useful to identify the particular company or companies.

Product names appearing herein are trademarks or registered trademarks of Takeda or their respective owners.

Forward-looking statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts , goals and plans for Takeda. Without limitation, forward-looking statements often include words such as “objectives”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensure”, “will”, “may”, “should”, “would”, “could”, “anticipate”, “estimate”, “plan” or similar expressions or their negative form. These forward-looking statements are based on assumptions about many important factors, including the following, that could cause actual results to differ materially from those expressed or implied by the forward-looking statements: economic circumstances surrounding the global business of Takeda, including general economic conditions in Japan and the United States; competitive pressures and developments; changes in applicable laws and regulations, including global healthcare reforms; challenges inherent in the development of new products, including the uncertainty of clinical success and the decisions of regulatory authorities and the timing thereof; the uncertainty of the commercial success of new and existing products; manufacturing difficulties or delays; interest rate and currency exchange rate fluctuations; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, such as the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in the countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to dispose of assets that are not essential to Takeda’s operations and the timing of such disposals; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the United States Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rules. Past performance is not an indicator of future results and Takeda’s results or statements in this press release may not be indicative and do not constitute an estimate, forecast, guarantee or projection of Takeda’s future results.

###

03 February 2022 CET/CEST DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de